Tuberculosis (TB), despite being a preventable and treatable disease, remains a significant global health concern. The key to controlling and eventually eliminating TB lies in accurate and timely diagnosis. This article aims to provide an in-depth review of the contemporary diagnostic approaches currently in use in the medical field.
The cornerstone of TB diagnosis is microbiological testing, which includes sputum smear microscopy, culture methods, and nucleic acid amplification tests (NAATs). The latter, such as Xpert MTB/RIF, have revolutionized TB diagnosis by providing rapid and accurate results, including drug resistance information.
Serological tests, which detect antibodies or antigens in the patient's blood, have been largely discredited due to their inconsistent and unreliable results. The World Health Organization (WHO) strongly advises against their use in TB diagnosis.
Radiological tests, particularly chest X-rays, are commonly used in TB diagnosis. However, they cannot confirm TB on their own due to the presence of other conditions that can mimic TB radiologically. Therefore, they are typically used in conjunction with microbiological tests.
IGRAs, which measure the immune response to TB antigens, represent a significant advance in latent TB diagnosis. However, they cannot distinguish between latent and active TB, necessitating further tests for confirmation.
WGS is an emerging tool in TB diagnosis and research. It offers the potential for comprehensive genetic profiling of the TB bacterium, aiding in the detection of drug resistance and strain typing. However, its application is currently limited by cost and technical complexity.
In conclusion, the diagnosis of TB has evolved significantly over the years, with a shift towards rapid, accurate, and comprehensive diagnostic tools. While challenges remain, particularly in resource-limited settings, the continued development and implementation of advanced diagnostic methods are crucial in the global fight against TB.
1.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
2.
Health researchers discuss Medicaid cancer screening trends, best practices
3.
Taking Charge of Your Cancer Journey.
4.
On all CAR-T products, the FDA is calling for a new boxed warning.
5.
Nivolumab Regimen Achieves Durable PFS in Advanced Hodgkin's Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Breaking Down Leukocytoclastic Vasculitis: Causes, Symptoms and Treatment
3.
Getting to Know RDW and SD: How They Relate to Anemia, Inflammation, and More
4.
A Review on Genetic Predispositions and Clinical Advancements of Multiple Myeloma Cancer
5.
AI-Powered Rehabilitation: A Game Changer for Hemophilia Management
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
3.
Navigating the Complexities of Ph Negative ALL - Part II
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation